The string of deals builds on the Trump administration’s push to link the nation’s drug prices to cheaper ones abroad.

The new pill is also aimed at people who are doing well on a single-tablet regimen, including Biktarvy, and want to switch to a new treatment.

HHS plans to name two deputy commissioners for technology and drugs, said two sources familiar with the matter.

The bigger issue at hand may be that many Americans fall into a large, uncertain middle ground – neither firmly pro-vaccine nor staunchly opposed.

Hims & Hers CEO Andrew Dudum spoke to CNBC about the FTC’s lawsuit against the company, compounded GLP-1 drugs and AI.

Doctors and other experts say that splitting the measles, mumps and rubella shot has no scientific basis and is unlikely to get off the ground. 

As Lilly widens its lead in the obesity race, Novo is still racing to win back market share and restore investor confidence in its pipeline.

Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from a previous guidance of $82 billion and $85 billion.

Merck cut its profit guidance due to a charge tied to its acquisition of biotech company Terns Pharmaceuticals. 

Humana maintained its 2026 adjusted profit outlook of at least $9 per share, which some analysts called a “disappointment” amid high expectations for insurers.